Sinotherapeutics (688247)2024-04-16 07:38Financial Performance - The company expects to achieve a net profit attributable to the parent company of 23.20 million yuan in Q1 2024, an increase of 15.48 million yuan, representing a year-on-year growth of 201%[10] - The projected operating revenue for Q1 2024 is 111.41 million yuan, which is an increase of 68.99 million yuan, reflecting a year-on-year growth of 163%[10] - In Q1 2023, the company reported an operating revenue of 42.42 million yuan and a net profit attributable to shareholders of 7.72 million yuan[3] - The net profit attributable to shareholders, excluding non-recurring gains and losses, for Q1 2024 is expected to be 21.54 million yuan, an increase of 16.17 million yuan, representing a year-on-year growth of 301%[2] - The significant increase in revenue and profit is attributed to the company's efforts in enhancing product sales and seizing market opportunities[12] Earnings Forecast - The earnings forecast period is from January 1, 2024, to March 31, 2024[10] - The financial data provided in the earnings forecast has not been audited by a registered accounting firm[6] - The company has not identified any major uncertainties that could affect the accuracy of the earnings forecast[13] Investment Risks - The company emphasizes the importance of investors being aware of investment risks related to the preliminary financial data[13] - The official financial data will be disclosed in the formal Q1 2024 report[13]